185 related articles for article (PubMed ID: 29808294)
1. Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.
Nadal R; Apolo AB
Curr Treat Options Oncol; 2018 May; 19(7):36. PubMed ID: 29808294
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
[TBL] [Abstract][Full Text] [Related]
3. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.
Apolo AB; Grossman HB; Bajorin D; Steinberg G; Kamat AM
Urol Oncol; 2012; 30(6):772-80. PubMed ID: 23218068
[TBL] [Abstract][Full Text] [Related]
4. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
Jackson-Spence F; Toms C; O'Mahony LF; Choy J; Flanders L; Szabados B; Powles T
Future Oncol; 2023 Mar; 19(7):509-515. PubMed ID: 37082935
[TBL] [Abstract][Full Text] [Related]
5. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy.
Mo Q; Li R; Adeegbe DO; Peng G; Chan KS
Commun Biol; 2020 Dec; 3(1):784. PubMed ID: 33335285
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy for bladder cancer finally comes into a new age.
Zibelman M; Plimack ER
Future Oncol; 2016 Oct; 12(19):2227-42. PubMed ID: 27402371
[TBL] [Abstract][Full Text] [Related]
8. Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer.
Vlachou E; Johnson BA; Baraban E; Nadal R; Hoffman-Censits J
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438640. PubMed ID: 38870453
[TBL] [Abstract][Full Text] [Related]
9. Multimodal management of muscle-invasive bladder cancer.
Park JC; Citrin DE; Agarwal PK; Apolo AB
Curr Probl Cancer; 2014; 38(3):80-108. PubMed ID: 25087173
[No Abstract] [Full Text] [Related]
10. Muscle-invasive urothelial bladder cancer: an update on systemic therapy.
Knollman H; Godwin JL; Jain R; Wong YN; Plimack ER; Geynisman DM
Ther Adv Urol; 2015 Dec; 7(6):312-30. PubMed ID: 26622317
[TBL] [Abstract][Full Text] [Related]
11. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer.
Jayaratna IS; Navai N; Dinney CP
Transl Androl Urol; 2015 Jun; 4(3):273-82. PubMed ID: 26816830
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy for muscle-invasive bladder cancer.
Black P; So A
Can Urol Assoc J; 2009 Dec; 3(6 Suppl 4):S223-7. PubMed ID: 20019990
[TBL] [Abstract][Full Text] [Related]
13. Current therapeutic strategies for invasive and metastatic bladder cancer.
Vishnu P; Mathew J; Tan WW
Onco Targets Ther; 2011; 4():97-113. PubMed ID: 21792316
[TBL] [Abstract][Full Text] [Related]
14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
16. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
17. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
18. A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?
Lan T; Ran S; Gao M; Li W; He W
Transl Androl Urol; 2024 Feb; 13(2):293-307. PubMed ID: 38481857
[TBL] [Abstract][Full Text] [Related]
19. Patterns of chemotherapy use in muscle-invasive bladder cancer in a tertiary centre.
Lim KY; Chu K; Rajarubendra N; Huang J; Pook D; Manohar P; Harper M; Donnellan S; Ranasinghe W
Bladder (San Franc); 2023; 10():e21200013. PubMed ID: 38163008
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
